港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维昇药业-B

47.550

-0.150-0.31%

成交量：54.21万

成交额：2,634.15万

市值：54.21亿

市盈率：-24.43

高：50.450

开：47.750

低：45.800

收：47.700

数据加载中...

总览公司新闻公告

老虎暗盘 | 维昇药业-B跌幅收窄，总市值超70亿港元

老虎资讯综合

"港股生长发育第一股"的增长逻辑，藏在维升药业-B(2561.HK)的稀缺创新里

维升药业IPO火爆逾70倍超购：基石阵容豪华

新股孖展统计 | 3月17日

新股认购 | 维昇药业-B认购倒计时，孖展申购已超36倍

老虎资讯综合

新股孖展统计 | 3月14日

新股孖展统计 | 3月13日

“港股生长发育第一股”启动招股，维升药业-B（2561.HK）都有哪些看头？

今起招股，"港股生长发育第一股"维升药业-B(2561.HK)获创始股东Sofinnova三轮追投

维升药业启动招股程序预计集资7.45亿港元

观点新媒体

新股招股 | 维昇药业-B今起招股，入场费7603.92港元

老虎资讯综合

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02561/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维昇药业-B","latestPrice":47.55,"timestamp":1753085318016,"preClose":47.7,"halted":0,"volume":542100,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"未开盘","change":-0.15,"latestTime":"07-21 16:08:38","open":47.75,"high":50.45,"low":45.8,"amount":26341495,"amplitude":0.097484,"askPrice":49,"askSize":2300,"bidPrice":47.55,"bidSize":2900,"shortable":0,"etf":0,"ttmEps":-1.946273,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753147800000},"marketStatusCode":0,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":47.7,"openAndCloseTimeList":[[1753061400000,1753070400000],[1753074000000,1753084800000]],"volumeRatio":22.036585231484235,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":22.036585231484235,"shares":113999999,"dividePrice":0,"high":50.45,"amplitude":0.097484,"preClose":47.7,"low":45.8,"week52Low":39.25,"pbRate":"20.53","psRate":"1783.30","week52High":69.15,"institutionHeld":0,"latestPrice":47.55,"committee":0.115385,"eps":-1.946273,"divideRate":0,"volume":542100,"delay":0,"ttmEps":-1.946273,"open":47.75,"prevYearClose":68.8,"prevWeekClose":47.7,"prevMonthClose":45.3,"prevQuarterClose":45.3,"fiveDayClose":44.7,"twentyDayClose":48.7,"sixtyDayClose":48.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02561\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1100286544","title":"老虎暗盘 | 维昇药业-B跌幅收窄，总市值超70亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100286544","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100286544?lang=zh_cn&edition=fundamental","pubTime":"2025-03-20 16:27","pubTimestamp":1742459271,"startTime":"0","endTime":"0","summary":"本周四， $维昇药业-B$ 暗盘大幅低开，随后跌幅收窄，截至发稿报64.6港元，跌幅6.1%：据悉，招股期截止时，预计其公开发售部分获得近70倍超额认购，国际发售部分同时获得超额申购。行业概况中国的非糖尿病内分泌药物市场规模呈现出强劲增长，由2018年的人民币117亿元增至2023年的人民币208亿元，年复合增长率为12.2%。筹资用途筹资用途方面，维昇药业-B预计全球发售所得款项净额约6.033亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"老虎暗盘 | 维昇药业-B跌幅收窄，总市值超70亿港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":1},{"id":"2520485863","title":"\"港股生长发育第一股\"的增长逻辑，藏在维升药业-B(2561.HK)的稀缺创新里","url":"https://stock-news.laohu8.com/highlight/detail?id=2520485863","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520485863?lang=zh_cn&edition=fundamental","pubTime":"2025-03-20 16:01","pubTimestamp":1742457664,"startTime":"0","endTime":"0","summary":"\"港股生长发育第一股\"维升药业IPO以破纪录姿态收官","market":"us","thumbnail":"https://img3.gelonghui.com/6d473-40730f54-561f-4303-887a-2a710db2849d.png?guru_height=250&guru_width=370","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/6d473-40730f54-561f-4303-887a-2a710db2849d.png?guru_height=250&guru_width=370"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1928974","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["HSTECH","HSCEI","BK4614","YANG","02561"],"gpt_icon":1},{"id":"2520651120","title":"维升药业IPO火爆逾70倍超购：基石阵容豪华","url":"https://stock-news.laohu8.com/highlight/detail?id=2520651120","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520651120?lang=zh_cn&edition=fundamental","pubTime":"2025-03-20 10:49","pubTimestamp":1742438956,"startTime":"0","endTime":"0","summary":"据悉，招股期截止时，预计其公开发售部分获得近70倍超额认购，国际发售部分同时获得超额申购。维升药业此次IPO引入了5名基石投资者，包括安科生物、苏州工业园区产业投资基金、Vivo Capital、药明生物、Reynold Lemkins等。维升药业此次IPO受到市场高度认可，其背后还有多重因素推动。首先，维升药业自身实力强劲，专注于内分泌疾病治疗领域，拥有强大的产品管线。近日，维升药业的大股东Ascendis Pharma在美上市的股票价格逆势创出年内新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032010521794baa104&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032010521794baa104&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561"],"gpt_icon":1},{"id":"2520546968","title":"新股孖展统计 | 3月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=2520546968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520546968?lang=zh_cn&edition=fundamental","pubTime":"2025-03-17 18:43","pubTimestamp":1742208211,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业(02561)、南山铝业(02610)正在招股中。截止3月17日，富途、耀才、辉立等券商合计为维升药业借出29.9373亿港元，超购逾38.9倍；为南山铝业借出1.4994亿港元，认购未足额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1262914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02610","02561"],"gpt_icon":0},{"id":"1121742959","title":"新股认购 | 维昇药业-B认购倒计时，孖展申购已超36倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1121742959","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121742959?lang=zh_cn&edition=fundamental","pubTime":"2025-03-17 16:48","pubTimestamp":1742201339,"startTime":"0","endTime":"0","summary":"本周一， $维昇药业-B$ 招股进入倒计时，公开认购将于明日8时截止，截止发稿孖展认购倍数已大36.07倍，融资申购金额26.89亿港元：公告显示，公司拟全球发售990万股股份，香港公开发售占10%，国际发售占90%，另有15%发售量调整权和15%超额配售权。根据弗若斯特沙利文的资料，2016年至2019年期间并无相关新药或剂型获批准，加上来自仿制药的竞争加剧，自2018年至2023年，后者的市场规模以6.6%的年复合增长率下降。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/e3e107f511c92fc222399099bfd06a69","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/e3e107f511c92fc222399099bfd06a69"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股认购 | 维昇药业-B认购倒计时，孖展申购已超36倍","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":1},{"id":"2519248879","title":"新股孖展统计 | 3月14日","url":"https://stock-news.laohu8.com/highlight/detail?id=2519248879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519248879?lang=zh_cn&edition=fundamental","pubTime":"2025-03-14 18:12","pubTimestamp":1741947135,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B(02561)正在招股中。截止3月14日，富途、耀才、辉立等券商合计为维升药业借出12.4749亿港元，超购逾15.6倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1262073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561"],"gpt_icon":0},{"id":"2519881856","title":"新股孖展统计 | 3月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2519881856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519881856?lang=zh_cn&edition=fundamental","pubTime":"2025-03-13 18:09","pubTimestamp":1741860599,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B(02561)正在招股中。截止3月13日，富途、耀才、辉立等券商合计为维升药业借出5.7997亿港元，超购逾6.7倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1261503.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561"],"gpt_icon":0},{"id":"2519071109","title":"“港股生长发育第一股”启动招股，维升药业-B（2561.HK）都有哪些看头？","url":"https://stock-news.laohu8.com/highlight/detail?id=2519071109","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519071109?lang=zh_cn&edition=fundamental","pubTime":"2025-03-13 12:57","pubTimestamp":1741841844,"startTime":"0","endTime":"0","summary":"维升药业正式开始招股","market":"hk","thumbnail":"https://img7.gelonghui.com/column/1.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/1.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1892069","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02561","BK4614","HSTECH","HSCEI","YANG"],"gpt_icon":1},{"id":"2519354071","title":"今起招股，\"港股生长发育第一股\"维升药业-B(2561.HK)获创始股东Sofinnova三轮追投","url":"https://stock-news.laohu8.com/highlight/detail?id=2519354071","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519354071?lang=zh_cn&edition=fundamental","pubTime":"2025-03-13 10:34","pubTimestamp":1741833265,"startTime":"0","endTime":"0","summary":"格隆汇3月13日｜今日，\"港股生长发育第一股\"维升药业开始招股。据市场消息透露，除创始股东Vivo Capital基石追投外， Sofinnova在招股前期也已启动完成第三轮追投。在过往全球医药投资中，Sofinnova凭借敏锐洞察力，成功布局多个高潜力项目。市场分析认为，创始股东连续三次追投维升药业，是基于对公司产品管线差异化优势及商业潜力的高度认可。据悉，2024年隆培促生长素在欧美地区的销售额高达2.02亿欧元，折合人民币约15.36亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031310345296435056&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031310345296435056&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","HSCEI","02561"],"gpt_icon":1},{"id":"2519071351","title":"维升药业启动招股程序 预计集资7.45亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2519071351","media":"观点新媒体","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519071351?lang=zh_cn&edition=fundamental","pubTime":"2025-03-13 10:11","pubTimestamp":1741831873,"startTime":"0","endTime":"0","summary":"观点网讯：3月13日，生物制药公司维升药业宣布启动招股程序，招股期从今日起至下周二，计划发售990万股，其中香港公开发售占10%，其余90%为国际发售。每股招股价介于68.44港元至75.28港元，预计集资总额约7.45亿港元。投资者入场费为7603.92港元，公司股票预计于3月21日在港交所挂牌交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250313101434a1da64ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250313101434a1da64ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561"],"gpt_icon":0},{"id":"1185055825","title":"新股招股 | 维昇药业-B今起招股，入场费7603.92港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185055825","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185055825?lang=zh_cn&edition=fundamental","pubTime":"2025-03-13 09:12","pubTimestamp":1741828320,"startTime":"0","endTime":"0","summary":"3月13日， $维昇药业-B$发布公告，于2025年3月13日至2025年3月18日招股，公司拟全球发售990万股股份，香港公开发售占10%，国际发售占90%，另有15%发售量调整权和15%超额配售权。于2022年、2023年及截至2024年9月30日止九个月，公司的综合亏损总额分别为人民币288.9百万元、人民币249.5百万元及人民币129.7百万元。行业概况中国的非糖尿病内分泌药物市场规模呈现出强劲增长，由2018年的人民币117亿元增至2023年的人民币208亿元，年复合增长率为12.2%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/e3e107f511c92fc222399099bfd06a69","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/e3e107f511c92fc222399099bfd06a69"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":71,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1746460800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2025-07-18","current":-27.275886,"percent":0.493151,"low":-30.760225,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"high":-17.514985,"avg":-26.483178,"sd":2.802831,"marketCap":5434311412},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862},{"date":"2025-07-04","current":-25.999842,"twenty":-28.345085,"median":-27.470681,"eighty":-26.039907,"marketCap":5189368655},{"date":"2025-07-11","current":-25.483255,"twenty":-28.252573,"median":-27.442177,"eighty":-25.700877,"marketCap":5081138134},{"date":"2025-07-18","current":-27.275886,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"marketCap":5434311412}],"updateTime":1753130683831}}}